“Carmat, the France-based developer of the Aeson artificial heart, announced it is in a critical financial situation and at risk of insolvency by the end of June 2025.
According to the company, current cash resources are insufficient to maintain operations beyond this month. Carmat said that despite ongoing efforts to secure additional financing, these talks have not yet produced concrete results.
The company claims it will continue discussions with existing shareholders and other potential investors in hopes of arranging bridge financing or a longer-term funding solution. However, Carmat acknowledged that if no agreement is reached soon, it may be forced to file for insolvency proceedings.
Carmat also noted that it is exploring options to restructure its debt and reduce operating costs, although these measures alone are unlikely to resolve the immediate liquidity shortfall.
The company said that it will provide updates as discussions progress but warned that its financial outlook remains highly uncertain. Founded in 2008, Carmat develops the Aeson artificial heart, which is aimed at treating patients with advanced heart failure.
As of now, Carmat continues to operate and remains in talks with various parties to secure the funding necessary to avoid insolvency and maintain its business activities.”
